Puma Biotechnology Inc

NASDAQ: PBYI
$5.13
-$0.04 (-0.8%)
Closing price April 23, 2024
Puma Biotechnology Inc is a Los Angeles-based biopharmaceutical firm dedicated to advancing cancer care globally. It specializes in developing innovative treatments, with a keen focus on breast cancer and HER2 mutation-positive solid tumors. Its flagship product, neratinib, is available in both oral and intravenous forms, targeting early stage to advanced HER2-positive breast cancer. Founded in 2010, Puma Biotechnology has formed strategic partnerships with several international companies, including Pfizer, to expand its reach and impact in the fight against cancer.

UBS Has Nine Biotech Buyout and Merger Candidates
The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility that some of the top names may also become takeover targets this year.
Lee Jackson
Published:

The 10 Stocks With the Biggest Gains This Year
Source: Finviz.comWith the end of the year two weeks away, 10 stocks have already had gains of more than 400%. Investors in these stocks have been, if they held them for the year, wildly...
Douglas A. McIntyre
Published:

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013
Source: ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in...
Lee Jackson
Published:
Last Updated: